CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
RELY-30
Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With CD30 CAR T Cells (RELY-30)
2 other identifiers
interventional
60
1 country
2
Brief Summary
The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers; they both have shown promise, but have not been strong enough to cure most patients. Investigators hope that both will work better together. Investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. They now want to test whether these genetically modified T cells given after chemotherapy will be more effective at killing cancer cells. The gene that will be put into the T cells makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma, but have not been strong enough to cure most patients. For this study, the anti-CD30 antibody has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric receptor-activated T cells (CD30.CAR T cells) seem to kill some of the tumor, but they don't last very long and so their chances of fighting the cancer are unknown. Several studies suggest that the infused T cells need room to be able to multiply and grow to accomplish their functions, and that this may not happen if there are too many other T cells in circulation. Because of that, doctors may use chemotherapy drugs to decrease the level of circulating T cells prior to the CD30.CAR T cells infusion. This is called "lymphodepletion" CD30.CAR T cells have previously been studied in lymphoma patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started May 2017
Longer than P75 for phase_1
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 23, 2016
CompletedFirst Posted
Study publicly available on registry
September 28, 2016
CompletedStudy Start
First participant enrolled
May 8, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2040
ExpectedJuly 25, 2025
July 1, 2025
8.9 years
September 23, 2016
July 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Patients with Dose-Limiting Toxicities (DLT)
Each treated patient will be followed for 6 weeks post the T-cell infusion for the evaluation of DLTs.
6 weeks
Secondary Outcomes (3)
Median Number of T cells transduced with the vector
15 years
Overall Response Rate
8 weeks
Mean Number of T cells transduced with the vector
15 years
Study Arms (1)
CD30.CAR T Cells
EXPERIMENTALEach patient will receive one infusion of CAR modified T cells. Unless post autologous transplant, patients will receive lymphodepleting chemotherapy as three daily doses of cyclophosphamide (Cy: 500mg/m2/day) together with fludarabine (Flu:30mg/m2/day) from 48 hours to 2 weeks before T cell infusion. Clofarabine (20 mg/m2/day) may be substituted for fludarabine.
Interventions
Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule: Dose Level One: 2x10\^7 cells/m2. Dose Level Two: 1x10\^8 cells/m2. Dose Level Three: 2x10\^8 cells/m2.
Eligibility Criteria
You may qualify if:
- Diagnosis of relapsed/refractory HL or NHL.
- CD30 positive tumor as assayed in a CLIA certified pathology laboratory (result can be pending at this time)
- Hgb ≥ 7.0 (may be a transfused value)
- Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
- Karnofsky or Lansky score of \> 60%
- Diagnosis of relapsed/refractory HL or NHL.
- CD30-positive tumor as assayed in a CLIA certified pathology laboratory.
- Age 16 to 75 for the first three patients on a dose level; thereafter, if no DLT, patients aged 12 to 75 can be treated on that dose level.
- Bilirubin 1.5 times or less than the upper limit of normal.
- AST 3 times or less than the upper limit of normal.
- Estimated GFR \> 70 mL/min.
- Pulse oximetry of \> 90% on room air
- EKG shows no significant arrhythmias
- Karnofsky or Lansky score of \> 60%.
- Available autologous T cells with greater than or equal to 15% expression of CD30CAR determined by flow-cytometry.
- +4 more criteria
You may not qualify if:
- Active infection with HIV or HTLV (can be pending at this time).
- Active bacterial, fungal or viral infection.
- Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks.
- Received anti-CD30 antibody-based therapy within the previous 4 weeks.
- Subjects with rapidly progressive disease, defined as kinetic failure to previous chemotherapy.
- Bulky disease (defined as a 10 cm or greater mass or mediastinal disease with a transverse diameter exceeding 33% of the transthoracic diameter).
- History of hypersensitivity reactions to murine protein-containing products.
- Pregnant or lactating.
- Tumor in a location where enlargement could cause airway obstruction.
- Current use of systemic corticosteroids at a dose equivalent to 0.5 mg/kg/day of prednisone or higher.
- Active hemorrhagic cystitis.
- Active bacterial, viral or fungal infection.
- Symptomatic cardiac disease (NYHA Class III or IV disease).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Houston Methodist Hospital
Houston, Texas, 77030, United States
Texas Children's Hospital
Houston, Texas, 77030, United States
Related Publications (1)
Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23.
PMID: 32701411DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Carlos A Ramos, MD
Baylor College of Medicine
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
September 23, 2016
First Posted
September 28, 2016
Study Start
May 8, 2017
Primary Completion
April 1, 2026
Study Completion (Estimated)
February 1, 2040
Last Updated
July 25, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share